TargetBeta
MEN1
menin 1
3 programs in company-led studies act on MEN1, from 3 companies: 2 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| revumenibrule | Syndax Pharmaceuticals | phase 3 | 64 running | KMT2A | ChEMBL |
| bleximenib | Johnson & Johnson | phase 3 | 42 running | KMT2A | a judged reading |
| Menin Inhibitor AZD3632 | AstraZeneca | phase 2 | 11 running | – | a judged reading |
Also acted on by the same programs
Conditions their studies are in
- Leukemia, Myeloid, Acute, 2 programs
- Precursor Cell Lymphoblastic Leukemia-Lymphoma, 2 programs
- Colorectal Neoplasms, 1 program
- Hematologic Neoplasms, 1 program
- Leukemia, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Feb 2027revumenib · Syndax Pharmaceuticals · phase 3 · NCT06226571
- Dec 29, 2028bleximenib · Johnson & Johnson · phase 3 · NCT04811560
- Feb 15, 2029Menin Inhibitor AZD3632 · AstraZeneca · phase 2 · NCT07155226
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.